Zacks Investment Research Downgrades LONZA GRP AG/ADR (OTCMKTS:LZAGY) to Sell

Share on StockTwits

LONZA GRP AG/ADR (OTCMKTS:LZAGY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Zacks.com reports.

According to Zacks, “Lonza Group AG operates as a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The company’s Life Science Ingredients segment produces nutrition ingredients for applications in nutrition (food, feed and pharmaceutical application) and chemical intermediates for the agricultural industry. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics. Lonza Group AG is headquartered in Basel, Switzerland. “

Shares of LONZA GRP AG/ADR stock opened at $34.36 on Friday. The company has a 50-day moving average of $34.20 and a 200 day moving average of $33.65. The firm has a market cap of $24.55 billion, a price-to-earnings ratio of 28.87, a PEG ratio of 2.12 and a beta of 1.17. LONZA GRP AG/ADR has a 1 year low of $24.70 and a 1 year high of $36.55.

About LONZA GRP AG/ADR

Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma&Biotech and Specialty Ingredients. Its products and services cover bio research solutions, such as stem cells primary cells and media, cell culture, transfection, exosomes, and assay solutions; electrophoresis of nucleic acids and proteins; primary and stem cell protocols; Hepatocytes/ADMETox solutions for microsomes and primary cell culture applications; and CytoSMART system, a live cell imaging and monitoring system.

Further Reading: Investing in Growth Stocks

Get a free copy of the Zacks research report on LONZA GRP AG/ADR (LZAGY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LONZA GRP AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LONZA GRP AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Agrolot  Market Cap Achieves $26,101.00
Agrolot Market Cap Achieves $26,101.00
Almeela Price Tops $0.0830 on Major Exchanges
Almeela Price Tops $0.0830 on Major Exchanges
Commercium Trading Down 20.1% Over Last Week
Commercium Trading Down 20.1% Over Last Week
Voise Achieves Market Cap of $41,495.00
Voise Achieves Market Cap of $41,495.00
Brokerages Expect Lipocine Inc  to Post -$0.17 Earnings Per Share
Brokerages Expect Lipocine Inc to Post -$0.17 Earnings Per Share
$0.91 EPS Expected for Victory Capital Holdings Inc  This Quarter
$0.91 EPS Expected for Victory Capital Holdings Inc This Quarter


© 2006-2019 Ticker Report